Lupin Limited

Lupin Limited
Company typePublic
BSE: 500257
NSE: LUPIN
IndustryPharmaceuticals
Founded1968; 56 years ago (1968)[1]
FounderDesh Bandhu Gupta[2]
Headquarters
Mumbai, Maharashtra[3]
,
India
Key people
Vinita D. Gupta (CEO)[4]
Nilesh Gupta (MD)[5][6]
Products
RevenueIncrease ₹19,656 crore (US$2.4 billion) (FY24)[7]
Increase ₹3,800 crore (US$460 million) (FY24)[7]
Increase ₹1,914 crore (US$230 million) (FY24)[7]
Total assetsIncrease ₹22,955 crore (US$2.8 billion)[8] (2023)
Total equityIncrease ₹12,464 crore (US$1.5 billion)[8] (2023)
Number of employees
20,000+ (2023)
Websitewww.lupin.com
Footnotes / references
[9]

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally.[10] The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

  1. ^ "Welcome to Lupin World". Lupinworld.com. Archived from the original on 8 June 2012. Retrieved 30 May 2013.
  2. ^ "Lupin goes all out to make up for lost chances - Corporate News". livemint.com. 8 February 2010. Retrieved 30 September 2010.
  3. ^ "Welcome to Lupin World". Lupinworld.com. Archived from the original on 7 June 2013. Retrieved 30 May 2013.
  4. ^ "Lupin outcome of board meeting". moneycontrol.com. 8 May 2013.
  5. ^ "Lupin's Vinita Gupta, Nilesh Gupta win EY Entrepreneur Award 2015". 12 February 2016.
  6. ^ "Board of Directors". Archived from the original on 7 October 2018. Retrieved 23 February 2016.
  7. ^ a b c "Investor Presentation Q4 FY24" (PDF). Lupin. Retrieved 29 May 2024.
  8. ^ a b "Lupin Profit & Loss Statements".
  9. ^ "Annual Report FY2021" (PDF). Lupin. Retrieved 17 May 2022.
  10. ^ "Top five generic drug makers". europeanpharmaceuticalreview.com. Retrieved 22 May 2020.